Connection

CLIONA ROONEY to Interleukin-2

This is a "connection" page, showing publications CLIONA ROONEY has written about Interleukin-2.
Connection Strength

0.521
  1. Can Treg elimination enhance NK cell therapy for AML? Blood. 2014 Jun 19; 123(25):3848-9.
    View in: PubMed
    Score: 0.363
  2. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
    View in: PubMed
    Score: 0.029
  3. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232.
    View in: PubMed
    Score: 0.028
  4. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362.
    View in: PubMed
    Score: 0.028
  5. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.
    View in: PubMed
    Score: 0.023
  6. The interleukin-10 homolog encoded by Epstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses. Virology. 1992 Dec; 191(2):773-82.
    View in: PubMed
    Score: 0.020
  7. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
    View in: PubMed
    Score: 0.016
  8. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.